Human respiratory syncytial virus vaccine antigen produced in plants

FASEB Journal

Volumn 14, Issue 14, 2000, Pages 2323-2328

  Belanger, Helene ^a   Fleysh, Nina ^a   Shannon, C O X ^a   Bartman, Greg ^a   Deka, Deepali ^a   Trudel, Michel ^b   Koprowski, Hilary ^a   Vidadi Yusibov, A N D ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Alfalfa mosaic virus; G protein; Respiratory tract; RSV

Indexed keywords

AMINO ACID; COAT PROTEIN; EPITOPE; GUANINE NUCLEOTIDE BINDING PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION;

ALFALFA MOSAIC VIRUS; ANIMALIA; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MEDICAGO SATIVA; NICOTIANA TABACUM; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; RNA VIRUSES; STAPHYLOCOCCUS PHAGE 187; SYNCYTIAL VIRUS; TABACUM;

EID: 0033729124     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0144com     Document Type: Article

References (38)

1. Epidemiology of respiratory syncytial virus infection in Washington D.C. III. Composite analysis of eleven consecutive yearly epidemics
2. Acute respiratory disease in infancy and childhood: Present understanding and prospects for prevention
3. A single-season epidemic with respiratory syncytial virus subgroup B2 during 10 epidemic years, 1978 to 1988
4. Detection of antibodies to respiratory syncytial virus attachment and nucleocapsid proteins with recombinant baculovirus-expressed antigens
5. Protective and disease-enhancing immune responses to respiratory syncytial virus
6. An epidemiologic study of altered reactivity, to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
7. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
8. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia
9. Antigenic and immunogenic analysis of group A and group B respiratory syncytial virus G proteins expressed from recombinant baculoviruses
10. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old
11. Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice
12. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived
13. Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein
14. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge
15. The respiratory syncytial virus subgroup B attachment glycoprotein: Analysis of sequence, expression from a recombinant vector, and evaluation as an immunogen against homologous and heterologous subgroup virus challenge
16. A subgroup-specific antigenic site in the G protein of respiratory syncytial virus forms a disulfide-bonded loop
17. Evaluation of subgroup-specific peptides of the G protein of respiratory syncytial virus for characterization of the immune response
18. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory, syncytial virus
19. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines
20. Identification of a linear epitope on the fusion glycoprotein of respiratory syncytial virus
21. Subgroup specific protection of mice from respiratory syncytial virus infection with peptides encompassing the amino acid region 174-187 from the G glycoprotein: The role of cysteinyl residues in protection
22. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies
23. Identification of a synthetic peptide as part of a major neutralization epitope of respiratory, syncytial virus
24. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection
25. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein
26. Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from Plasmodium falciparum circumsporozoite protein as antigens
27. Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1
28. A new tobacco mosaic virus vector and its use for the systemic production of angiotensin-I-converting enzyme inhibitor in transgenic tobacco and tomato
29. Development of cowpoea mosaic virus as a high-yielding system for the presentation of foreign peptides
30. Expression of an animal virus antigenic site on the surface of a plant virus particle
31. Presentation of a foreign peptide on the surface of tomato bushy stunt virus
32. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1
33. Immunization against rabies with plant-derived antigen
34. N-terminal basic amino acids of alfalfa mosaic virus coat protein involved in the initiation of infection
35. Replication of incomplete alfalfa mosaic virus genome in plants transformed with viral replicase genes
36. Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector
37. Monoclonal antibodies that protect against respiratory syncytial virus infection in mice